Pioglitazone decreased CD40/CD40L expression on human umbilical vein endothelial cells induced by oxidized low-density lipoprotein

Clinica Chimica Acta

Volumn 370, Issue 1-2, 2006, Pages 94-99

  Jiang, De qian ^a   Chu, Luo xiang ^a   Liu, Zhao yun ^a   Zhang, Shun bao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CD40 CD40L; Human umbilical endothelial vein cells; LOX 1; Oxidized LDL; Pioglitazone

Indexed keywords

CD40 LIGAND; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PIOGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIGENS, CD40; CD40 LIGAND; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS, LDL; SCAVENGER RECEPTORS, CLASS E; THIAZOLIDINEDIONES; UMBILICAL VEINS;

EID: 33746102184     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.01.026     Document Type: Article

References (29)

1. Lutgens E., and Daemen M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12 (2002) 27-32
2. Mach F., Schönbeck U., Suhkova G., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94 (1997) 1931-1936
3. Reul R.M., Fang J.C., Denton M.D., et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 64 (1997) 1765-1774
4. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
5. Cipollone F., Mezzetti A., Porreca E., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation 106 (2002) 399-402
6. Schonbeck U., Sukhova G.K., Schonbeck U., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution established atherosclerosis in mice. Proc Natl Acad Sci U S A 97 (2000) 7458-7463
7. Mach F., Schönbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
8. Mehta J.L., and Li D.Y. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 248 (1998) 511-514
9. Lemberger T., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12 (1996) 335-363
10. Mehta J.L., Hu B., Chen J., and Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 23 (2003) 2203-2208
11. Li D., Liu L., Chen H., Sawamura T., and Mehta J.L. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 816-821
12. Hessler J.R., Morel D.W., Lewis L.J., and Chisolm G.M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Atherosclerosis 3 (1983) 215-222
13. Gearing A.J., Hemingway I., Pigott R., Hughes J., Rees A.J., and Cashman S.J. E-Selectin, ICAM-1, VCAM-1: pathological significance. Ann N Y Acad Sci 667 (1992) 324-331
14. Chen M., Masaki T., and Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95 (2002) 89-100
15. Yellin M.J., Brett J., Baum D., et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 182 (1995) 1857-1864
16. Berliner J.A., and Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20 (1996) 707-727
17. Hakkinen T., Karkola K., and Yla-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions: colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 437 (2000) 396-405
18. Schönbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
19. Peng D.Q., Zhao S.P., Li Y.F., Li J., and Zhou H.N. Elevated soluble CD40 ligand is related to the endothelial adhesion, molecules in patients with acute coronary syndrome. Clin Chim Acta 319 1 (2002) 19-26
20. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
21. Li D.Y., Zhang Y.C., Phillips M.I., Sawamura T., and Mehta J.L. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 84 (1999) 1043-1049
22. Kume N., Murase T., Moriwaki H., et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 83 (1998) 322-327
23. Li D., and Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101 (2000) 2889-2895
24. Mehta J.L., and Li D.Y. Identification, regulation and function of LOX-1, a novel receptor for ox-LDL. J Am Coll Cardiol 39 (2002) 1429-1435
25. Chiba Y., Ogita T., Ando K., and Fujita T. PPARγ ligands inhibit TNF-α-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun 286 (2001) 541-546
26. Li D.Y., Yang B.C., and Mehta J.L. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol 275 (1999) H568-H576
27. Luo Y., Liang C., Xu C., et al. Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. J Cardiovasc Pharmacol 44 3 (2004) 381-385
28. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
29. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669